Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir for Post-Exposure Prophylaxis of Ebola
NCT04268966Phase 2Withdrawn
- Sponsor
- Chimerix Inc.
- Start
- Oct 2014
- Primary completion
- Nov 2015
- Modality
- Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label, single-arm trial of brincidofovir in Ebola virus disease (EVD), sponsored by Chimerix Inc. Primary endpoint: Safety and tolerability of BCV at 8 weeks. Planned start Oct 2014; status: withdrawn.
02
Drugs
brincidofovir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04268966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268966.